Invivyd Faces Nasdaq Delisting After Stock Sinks Below $1.00

summarizeSummary

Invivyd received a Nasdaq delisting notice on July 23, 2026 after its stock price closed below $1.00 for 30 consecutive days. The company has until January 19, 2027 to regain compliance.

check_boxKey Events · Legal and Risk Events · IVVD

• Nasdaq Delisting Notice Received

  On July 23, 2026, Invivyd received a deficiency letter from Nasdaq because its stock closed below $1.00 for 30 consecutive business days, violating the Minimum Bid Price Requirement.

• Compliance Deadline Set

  The company has until January 19, 2027 to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. If not met, it may qualify for a second 180-day period by transferring to the Nasdaq Capital Market.

• Existential Risk Amplified

  The delisting notice follows the FDA's termination of emergency use authorization for PEMGARDA, Invivyd's only commercial product, and ongoing cash burn from Phase 3 trials for VYD2311. A delisting would further impair capital-raising ability.

• Potential Reverse Split Ahead

  To regain compliance, Invivyd will likely need to implement a reverse stock split, which would mechanically boost the share price but does not address underlying business challenges.

auto_awesomeAnalysis · IVVD · Life Sciences

After closing below $1.00 for 30 consecutive business days, Invivyd's stock has triggered a Nasdaq deficiency letter. The company now has until January 19, 2027 to regain compliance—typically through a reverse split or sustained price recovery. Failure would mean delisting to the OTC, severely limiting liquidity and institutional access. This development arrives just weeks after the FDA terminated emergency use authorization for its only commercial product, PEMGARDA, and as the company burns cash on Phase 3 trials for VYD2311. The delisting notice compounds existential risk for a company already fighting for survival.